Adaptimmune's Tecelra Gains FDA Approval for Synovial Sarcoma

The FDA has granted Adaptimmune expedited clearance for Tecelra (afami-cel), a medication used to treat metastatic or incurable synovial sarcoma. Tecelra is the first TCR-T therapy to hit the market, the first designed cell therapy for a solid tumour, and the first novel medicine in the indication in over ten years. The 16-year-old firm, which has drawn and lost alliances with various pharmaceutical behemoths including GSK, Astellas, and most recently Roche, is also celebrating its first clearance.

T-cells may be created to target and eradicate a variety of solid tumour malignancies thanks to the company's exclusive engineered T-cell receptor (TCR) technology. Tecelra represents a critical turning point for both the business and the development of cell therapy. The one-time treatment is listed as $727,000. The patient who can be addressed population in the US is roughly 400 per year.

Rare solid tumour malignancies called sarcomas typically affect young individuals and originate in the soft tissues and bones. Five to ten percent of newly diagnosed soft tissue sarcomas in the United States each year are synovial in nature. Twenty percent of patients survive for five years, and the majority get many lines of therapy.

The approval is predicated on the findings of the 44-patient SPEARHEAD-1 research, in which afami-cel had an overall response rate of 43%, with 4.5% of patients experiencing the complete removal of their malignancy. The experiment found that the median treatment-free period for patients who responded to Tecelra was 17 months. The research did not report any treatment-related fatalities, yet Tecelra can have major adverse effects, such as neurotoxicity and cytokine release syndrome.

The expedited approval will need a confirmatory trial. By the end of this year, Adaptimmune hopes to have six to ten approved treatment centres operating; by the end of 2025, that number will have increased to thirty locations across the US.

After going public in 2015, Adaptimmune was in serious financial trouble in April due to Genentech's $3 billion withdrawal from a collaboration in which the company was working on two allogenic T-cell treatments that may target up to five different targets. The rights to uza-cel, a MAGE-4A TCR T-cell treatment that Adaptimmune is testing in phase 2 for ovarian cancer, were acquired by Galapagos for $665 million. Adaptimmune's Tecelra launch will be aided by the $100 million upfront payment from the Galapagos transaction.